The Hammersmith Score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden.
James Alexander KorolewiczBernhard ScheinerClaudia A M FulgenziAntonio D'AlessioAlessio CortelliniChynna PascualAman MehanSarah PartridgeDorothy M GujralWaleed MohammedOreoluwa MohammedAneta GrzesiakLauren BookerSusan CleatorTzveta PokrovskaWaqar SaleemJames RackieYasmine NeedhamJonathan KrellIain McNeishLaura TookmanWon-Ho Edward ParkMuzamil AsifJoanne S EvansDavid J PinatoPublished in: Chemotherapy (2024)
HS is a validated prognostic index for patients with advanced cancer treated in the context of modern EPCTs, independent of tumour burden. HS is a simple, inexpensive prognostic tool to optimise referral for EPCT.